Join our daily newsletter At The Bell to receive exclusive market insights
Tryptamine Therapeutics (ASX:TYP) has confirmed it’s wrapped up its first-ever IV psilocin injections in 11 patients being used to establish baseline dosage data.
The company’s Phase 1b study saw patients administered the psychoactive byproduct via IV over 2-and-a-half hours. All patients were discharged without incident.
This latest activity was established not to assess outcomes necessarily but to establish baseline safety data for further trials investigating the effects on the drug on the mind and subsequent outcomes post-administration.
The company is particularly keen to figure out what the best infusion rate is with regards to dosage, as this will de-risk further studies and trials.
A safety review is underway; it’s also hoped the data from this Phase 1b study can help find the ‘ideal dose’ for therapeutic contexts in the sense of effects of the drug.
Tryptamine Therapeutics reported on Monday that the outcomes of an oral psilocybin trial saw patients with binge eating disorders reduce those episodes by over 80%.
“Defining therapeutic, reproducible blood level results in patients is one of the key pillars to the Company’s strategy and we look forward to reviewing results,” TYP CEO Jason Carroll said.
“This study was pivotal for the Company, as it allowed us to learn and refine the ideal infusion dose level for TRP-8803 to ensure that circulating blood concentrations of psilocin remain consistent and within the proposed therapeutic zone in participants over a two and a half hour period.
“These results will then allow us to advance additional clinical trials using TRP-8803, in close collaboration with our partners and the Therapeutic Goods Administration.”
It’s the latest update from one small niche of the ASX – healthcare juniors using psychedelic drugs to, ideally, treat mental health conditions. True believers and self-medicators are quite enthusiastic for the thematic; TYP is joined at least by Emyria (ASX:EMD) based in WA.
Not long ago, Emyria was more interested in selling medicinal cannabis patient outcome data to hospitals and other entities; it recently became interested in psychedelics.
TYP last traded at 2cps.
-1200x645-380x200.jpg)
